Juno Therapeutics Inc

Maxim Group Initiates Buy On Juno Therapeutics Inc; Sees 52% Upside For The Stock

In a research report released today, Maxim Group analyst Jason McCarthy initiated coverage on shares of Juno Therapeutics Inc (NASDAQ:JUNO) with a Buy rating and a …

Jason Cohen — June 17, 2015, 7:38 PM EDT

Juno Therapeutics Inc (JUNO)’s Multiple Sources of Technology May Prove To Be A Competitive Advantage Over Time: J.P. Morgan

Juno Therapeutics Inc (NASDAQ:JUNO) shares have taken off, adding 13.72% to trade at $60.

Jason Cohen — June 2, 2015, 10:53 AM EDT

J.P. Morgan Provides Key Takeaways From Juno Therapeutics Inc ASCO Presentations

J.P.

Jason Cohen — June 1, 2015, 8:29 PM EDT

Stock Update (NASDAQ:JUNO): Juno Therapeutics Inc Appoints Dr. Hyam I. Levitsky as Chief Scientific Officer

Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced the appointment of …